Dr. Nissen consults for many pharmaceutical companies, including companies making or developing diabetes drug.
FORBES: Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings
Nissen MD, the Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic.
FORBES: Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings
"As some of you know, I've been critical of the agency in recent years, " Nissen said.
Nissen argues that these patients should have been an ideal group for proving Zetia's benefits.
The 502-patient Reversal trial was funded by Pfizer and led by the Cleveland Clinic's Steven Nissen.
The New England Journal analysis, from Cleveland Clinic cardiologist Steven Nissen, was front-page news.
It had planned to release them on a Wednesday, but Nissen's study came out on Monday.
Steven Nissen, chairman of cardiology at the Cleveland Clinic, says he is very worried about diclofenac.
In the NEJM editorial, Nissen spins what he sees as the worrisome story of these drugs.
Nissen headed a multi-center trial to see if the drug could reduce cholesterol buildup in arteries.
However, industry may want to take note as Nissen's critiques become even more wide-ranging.
"That was extremely unlikely, " says Steven Nissen, the Cleveland Clinic cardiologist who led the trial.
"While this is concerning, it is not definitive, " says Steven Nissen of the Cleveland Clinic.
"It's a window into the future, " says Steven Nissen, a cardiologist at the Cleveland Clinic.
Today, Nissen says he wishes that he had not gone on the AtheroGenics conference call.
It was eventually withdrawn worldwide because of the very liver toxicity that worried Nissen.
Nissen sent the results to The New England Journal of Medicine, which rushed to publish them.
That, in turn, would let academic watchdogs like Nissen troll for side effects more easily.
"It's really the next generation, " says Steven Nissen , vice-chairman of cardiology at the Cleveland Clinic.
"I don't think anyone knows if they prevent heart attacks, " says Cleveland Clinic cardiologist Steven Nissen.
The next speaker after Nissen was Robert Califf, the vice chancellor for clinical research at Duke University.
Nissen says that the study, and other trials being funded by Pfizer, will determine whether torcetrapib works.
When Nissen got back to Cleveland, he showed the results to Eric Topol, the clinic's top cardiologist.
Nissen argues that those studies provide more evidence of the increased risk of heart problems with Avandia.
The DREAM results were "very troubling, " Nissen told Forbes.com at the time (see: "Glaxo's Faustian Pill").
It is possible, Nissen says, that Celebrex could be safe at its labeled dose of 200 mg.
"They did a great job, " says Steven Nissen of the Cleveland Clinic, who was on the panel.
But the FDA had big enough doubts that it didn't even ask Nissen's panel for a vote.
"We really need to know whether cox-2 inhibitors are safe for patients with heart disease, " Nissen says.
"We need a large-scale clinical trial that compares the most popular drugs in the class, " says Nissen.
应用推荐